

# Index

## Note:

For cutaneous lymphomas, the word “primary” has been omitted; all entities are listed under specific terms (i.e., not under “cutaneous” followed by specific terminology)  
Page numbers in bold refer to tables, those in italics refer to figures.

## Abbreviations:

NOS – not otherwise specified

- acquired immunodeficiency syndrome (AIDS) 275, 277, 367  
*see also* HIV infection, cutaneous lymphomas and pseudolymphomas in HIV patients
- acral pseudolymphomatous angiokeratoma in children (APACHE) 352, 355, 356, 357  
pre-tibial lymphoplasmacytic plaque vs 393
- acrodermatitis chronica atrophicans  
association with marginal zone lymphoma 209, 216  
pseudolymphomatous 352, 361–362, 362, 363
- actinic dermatitis, chronic *see* chronic actinic dermatitis
- actinic reticuloid 77, 352–354, 352, 353  
erythroderma in 353, 366, 366  
histopathology 353, 353  
progression to T-cell lymphoma 353  
treatment 354
- acupuncture, pseudolymphoma in 381
- acute febrile neutrophilic dermatosis *see* histiocytoid Sweet’s syndrome; Sweet’s syndrome
- acute lymphoblastic leukemia 320, 321, 325  
*see also* lymphoblastic lymphomas, cutaneous
- acute myeloid leukemia 297, 301  
*see also* myelogenous leukemia, cutaneous manifestations
- adipocytes, rimming 106, 123, 123, 125, 126, 129, 377, 378
- adolescents, cutaneous lymphomas *see* children/adolescents, cutaneous lymphomas
- adult T-cell leukemia/lymphoma, cutaneous 172–175  
children/adolescents 343  
classification 172  
clinical features 172, 173  
histopathology and immunophenotype 172–173, 174  
molecular genetics 172–173  
post-transplant 265  
smoldering type 173  
treatment and prognosis 173  
variants 172
- aggressive cutaneous cytotoxic lymphomas 120, 133–154  
classification issues 133  
cytomorphology 133–134  
cytotoxic phenotype and markers 133  
overlap between different entities 133  
primary and secondary cutaneous involvement 134  
*see also* aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma; extranodal NK/T-cell lymphoma, nasal type;  $\gamma/\delta$  T-cell lymphoma, cutaneous
- aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma 9, 133, 134–137  
children/adolescents 343  
clinical features 134, 134, 135  
histopathology 134–136, 135, 136  
immunophenotype 136, 136, 137  
molecular genetics 137  
prognosis 137  
treatment 137
- aggressive natural killer (NK)-cell leukemia 318, 318, 319
- AIDS 275, 277, 367  
*see also* HIV infection, cutaneous lymphomas
- alemtuzumab 59, 80, 291, 318
- “aleukemic” leukemia cutis 287, 296, 300, 302, 306, 320
- Alibert, French dermatologist 11
- Alibert-Bazin, type of mycosis fungoides 11
- alitretinoin 59
- ALK-1 expression  
anaplastic large cell lymphoma 99, 100, 108, 108  
anaplastic large cell lymphoma in children 342  
anaplastic large cell lymphoma, HIV-related 277  
intravascular large NK/T-cell lymphoma 239
- allogeneic stem cell transplantation *see* stem cell transplantation
- alopecia  
actinic reticuloid 353  
benign follicular mucinosis 43  
follicle center lymphoma 185, 186  
pilotropic mycosis fungoides 35, 36, 36–40, 39, 41, 54  
Sézary syndrome 74, 75, 366
- alopecia mucinosa 36, 38, 39
- alopecia neoplastica 186
- alopecia universalis 36
- AML *see* myelogenous leukemia, cutaneous manifestations
- amyloid deposits 212, 251, 251
- ANA 121, 122, 376, 377
- anaplastic large cell lymphoma, cutaneous 99–109  
ALK-1 positive 99, 100, 108, 108, 342  
angiocentric/angiodestructive variant 105, 107  
benign intralymphatic proliferation of T-cell lymphoid blasts vs 398  
children/adolescents 342  
clinical features 100, 101–102  
histopathologic variants 104–107  
histopathology 101–107, 102–107, 114–115, 114–115  
HIV-related 100, 275, 277  
treatment 277  
Hodgkin lymphoma vs 331, 332, 333  
immunophenotype 106, 114, 102–106, 115  
inflammatory type 102, 104  
intralymphatic CD30+ large T-cell lymphoma as variant 114–115, 239, 240–241  
intralymphatic spread 114–115, 114–115, 240–241  
lymphomatoid papulosis relationship 85, 99  
molecular genetics 108  
myxoid variant 106, 107  
palisading granuloma-like pattern 102, 104  
post-transplant 265, 268  
prognosis 108  
signet-ring morphology 102, 104  
small cell variant 102, 103  
TNM classification 100, 100  
treatment 108
- anaplastic lymphoma kinase (ALK) *see* ALK-1 expression
- anetoderma  
follicle center lymphoma 186  
marginal zone lymphoma (conventional) 203  
marginal zone lymphoma (lymphoplasmacytic) 209, 210  
mycosis fungoides 33, 51–52
- angiocentricity/angiodestruction 3
- adult T-cell leukemia/lymphoma 172
- aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma 136  
anaplastic large cell lymphoma 105, 107  
blastic plasmacytoid dendritic cell neoplasm 306, 308  
cutaneous  $\gamma/\delta$  T-cell lymphoma 139, 142  
cutaneous manifestations of myelogenous leukemia 297  
diffuse large B-cell lymphoma 260, 260  
diffuse large B-cell lymphoma, leg type 223, 224  
extranodal NK/T-cell lymphoma, nasal type 144, 145, 146  
 $\gamma/\delta$  T-cell lymphoma, cutaneous 142  
hydroa vacciniforme 374  
hydroa vacciniforme-like T-cell lymphoma 179  
lymphomatoid granulomatosis 254, 255

- angiocentricity/angiodestruction (*cont'd*)  
 lymphomatoid papulosis 88, 89, 93–94, 95  
 lymphoproliferative disorders in immunodeficiency 281  
 mycosis fungoides 22, 26  
 peripheral T-cell lymphoma NOS 156  
 pseudolymphomas associated with lupus erythematosus 379, 405, 405  
 subcutaneous panniculitis-like T-cell lymphoma 123  
 T-cell/histiocyte-rich B-cell lymphoma 258  
 angiodestruction *see* angiocentricity/angiodestruction  
 angioendotheliomatosis  
 malignant 232  
 reactive 396–397  
 intravascular large B-cell lymphoma vs 235  
 angioimmunoblastic lymphadenopathy *see* angioimmunoblastic T-cell lymphoma  
 angioimmunoblastic T-cell lymphoma 6, 176–179  
 children/adolescents 343  
 clinical features 176, 177  
 histopathology and immunophenotype 176–177, 177, 178  
 molecular genetics 176–177  
 treatment and prognosis 177–178  
 angiosarcoma, pseudolymphomatous 399, 400  
 angiotropic large B-cell lymphoma *see* intravascular large B-cell lymphoma  
 angiotropic large T-cell lymphoma *see* intravascular large NK/T-cell lymphoma  
 annular lichenoid dermatitis of youth 361, 361  
 antibiotics, marginal zone lymphoma 208, 210, 216  
 anti-CD20 treatment *see* rituximab  
 anti-CD52 treatment 59, 80, 317  
 antigen retrieval techniques 4  
 antinuclear antibodies (ANA) 121, 122, 376, 377  
 APACHE *see* acral pseudolymphomatous angiokeratoma in children (APACHE)  
 acquired immunodeficiency syndrome *see* AIDS  
 arthropod bite reactions  
 CD30+ T-cell pseudolymphoma 367, 368  
 exaggerated *see* exaggerated arthropod bite-like reaction  
 follicle center lymphoma resembling 185  
 myelogenous leukemia resembling 303  
 peripheral T-cell lymphoma resembling 155, 156  
 persistent nodular 155, 369–371, 370, 371  
 ATLL *see* adult T-cell leukemia/lymphoma, cutaneous  
 atopic dermatitis  
 erythroderma in 365, 366, 366  
 pseudolymphomatous 362–363, 363, 364  
 atypical lymphoid proliferation 351, 413–414, 414  
 autoimmune disorders  
 marginal zone lymphoma and 202  
 $\gamma/\delta$  T-cell lymphoma association 139  
 subcutaneous panniculitis-like T-cell lymphoma and 120, 122, 125  
 autologous stem cell transplantation *see* stem cell transplantation  
 azathioprine 354  
 bacteria, lymphoma association 6–7  
*see also* *Borrelia burgdorferi*  
 bath-PUVA  
 actinic reticuloid 354  
 mycosis fungoides 57  
 B-cell chronic lymphocytic leukemia (B-CLL), cutaneous manifestations 287–295  
*Borrelia burgdorferi* association 287, 288  
 clinical features 287, 288, 293  
 herpes viruses associated 287, 288  
 high-grade lymphoma development 291  
 histopathology 287–289, 289, 293  
 proliferation centers 288, 289  
 immunophenotype 289, 290, 291  
 large cell transformation 291, 291  
 mycosis fungoides, composite lymphoma 28, 289, 293–294  
 prognosis 289, 291  
 Richter syndrome 291, 291  
 treatment 291  
 B-cell lymphomas, cutaneous 183  
 classification 183  
 incidence 183  
 B-cell prolymphocytic leukemia 319  
 B-CLL *see* B-cell chronic lymphocytic leukemia (B-CLL), cutaneous manifestations  
 benign angioendotheliomatosis, intralymphatic histiocytosis vs 396  
*see also* angioendotheliomatosis, reactive  
 benign intralymphatic proliferation of T-cell lymphoid blasts 239, 397–398, 398  
 bexarotene  
 lymphomatoid papulosis 98, 99  
 mycosis fungoides 58, 61  
 Sézary syndrome 79  
 BIOMED-2 assay 5  
 biopsies, technique 3  
 blastic plasmacytoid dendritic cell neoplasm 296, 299, 306–316  
 B-lymphoblastic lymphoma vs 322–323  
 children/adolescents 344  
 clinical features 306, 307, 313, 314  
 histopathology 306–307, 307–309  
 immunophenotype 308–311, 309–311  
 molecular genetics 311  
 myelogenous leukemia relationship 306  
 myeloid leukemia vs 310  
 treatment 311  
 prognosis 311, 313  
 blastoid marginal zone cells 204–205, 205, 208  
 “blueberry muffin” baby 296, 297  
 blood vessels *see* endothelial cells  
 B-lymphoblastic lymphoma, cutaneous 320–323  
 clinical features 320, 321  
 differential diagnosis 322–323  
 histopathology 320, 321  
 immunophenotype 320–321, 322  
 molecular genetics 321–322  
 treatment and prognosis 323  
 borderline disorders 8, 413  
 “borderline” cutaneous CD30+ lymphoproliferative disorders 85, 109–110, 342  
*Borrelia* infection *see* *Borrelia afzelii*; *Borrelia burgdorferi*  
*Borrelia afzelii* 361  
*Borrelia burgdorferi*  
 B-CLL 287, 288, 292  
 cutaneous plasmacytosis 391  
 diffuse large B-cell lymphoma, leg type 220  
 follicle center lymphoma and 186  
 lymphocytoma cutis associated with 287, 341, 351, 380, 381, 382, 383, 383, 384  
 lymphomas and 6  
 marginal zone lymphoma 201, 202  
 conventional type 202, 208  
 lymphoplasmacytic variant 202, 208, 209, 210, 216  
 mycosis fungoides 11  
 pseudolymphomas and 351, 362  
*Borrelia* lymphocytoma *see* *Borrelia burgdorferi*, lymphocytoma cutis associated with  
 bortezomib  
 EBV+ diffuse large B-cell lymphoma of elderly 247  
 mycosis fungoides 59  
 break-apart probes 6  
 brentuximab  
 anaplastic large cell lymphoma 109  
 EBV+ diffuse large B-cell lymphoma of elderly 247  
 lymphomatoid papulosis 98  
 Brocq, French dermatologist 7, 13, 34  
 bullous pemphigoid, pseudolymphomatous 398  
 Burkitt lymphoma, cutaneous manifestations 252–254  
 children/adolescents 344  
 clinical features 252, 253  
 histopathology, immunophenotype 252–254, 253  
 molecular genetics 254  
 treatment and prognosis 252  
 variants 252  
 Burkitt lymphoma-like disorders 224, 224  
 in HIV infection 275  
 Caelyx© 59  
 Campath© *see* anti-CD52 treatment  
 capillary hemangioma, colonization in intravascular large B-cell lymphoma 232–233, 234  
 carcinoma, lymphoepithelial-like 399, 399  
 Castleman disease 256, 391  
 cutaneous manifestations 392, 392–393  
 differential diagnosis 392–393  
 forms/variants 392  
 multicentric variant 392, 393  
 CD antigens 5  
 CD4+/CD56+ hematodermic neoplasm *see* blastic plasmacytoid dendritic cell neoplasms  
 CD4+ small–medium T-cell lymphoma, cutaneous 163–171  
 CD8+ variant *see* indolent CD8+ lymphoid proliferation of the face/ear  
 children/adolescents 343  
 classification issues 163  
 clinical features 163, 169  
 diagnostic features 163  
 differential diagnosis 163  
 follicular T-helper lymphocytes and 163, 167–168  
 histopathology 164, 164, 169  
 immunophenotype 164, 165, 166, 170  
 peripheral T-cell lymphoma vs 168  
 prognosis 166, 169  
 treatment 166  
 CD8+ infiltrates in HIV patients 352, 367  
 CD8+ cytotoxic T-cell lymphoma, aggressive epidermotropic *see* aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma  
 CD8+ lymphoid proliferation of the face/ear *see* indolent CD8+ lymphoid proliferation of the face/ear  
 CD30+ lymphoproliferative disorders, cutaneous 27, 85–119  
 borderline cases 85, 109, 110  
 cutaneous Hodgkin lymphoma vs 333  
 lymphomatoid drug reaction vs 379  
*see also* anaplastic large cell lymphoma; lymphomatoid papulosis  
 CD30+ T-cell pseudolymphomas 352, 367–368, 368  
 causes 368  
 chemotherapy  
 adult T-cell leukemia/lymphoma 173, 174  
 aggressive NK-cell leukemia 318  
 anaplastic large cell lymphoma 108–109  
 angioimmunoblastic T-cell lymphoma 177, 178

- B-CLL 291  
 blastic plasmacytoid dendritic cell neoplasm 311, 313  
 B-lymphoblastic lymphoma 323, 323  
 Burkitt lymphoma 253, 253  
 Castleman disease 392  
 CD4+ small-medium T-cell lymphomas 166  
 CD8+ cutaneous infiltrates in HIV patients 367  
 cutaneous manifestations of B-CLL 291  
 cutaneous peripheral T-cell lymphoma NOS 157  
 diffuse large B-cell lymphoma, leg type 226, 227  
 EBV+ diffuse large B-cell lymphoma of elderly 247, 247  
 extracavitary primary effusion lymphoma 249  
 extramedullary hematopoiesis 395  
 follicle center lymphoma 195, 197  
 hydroa vacciniforme-like lymphoma 190, 191  
 intralymphatic CD30+ large T-cell lymphoma 239  
 intravascular large B-cell lymphoma 235, 236  
 intravascular large NK/T-cell lymphoma 238  
 lymphomatoid granulomatosis 256, 256  
 lymphomatoid papulosis 98  
 mantle cell lymphoma 247  
 marginal zone lymphoma 208, 210, 212  
 myelogenous leukemia 301  
 mycosis fungoides 59  
 plasmablastic lymphoma 258  
 post-transplant lymphoproliferative disorders 268, 271  
 Sézary syndrome 80  
 subcutaneous panniculitis-like T-cell lymphoma 125–127  
 T-lymphoblastic lymphoma 325, 325  
 children/adolescents, cutaneous lymphomas 341–350  
 adult T-cell leukemia/lymphoma 343  
 aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma 343  
 anaplastic large cell lymphoma 342  
 angioimmunoblastic T-cell lymphoma 343  
 blastic plasmacytoid dendritic cell neoplasms 344  
 Burkitt lymphoma 344  
 CD4+ small-medium T-cell lymphomas 343  
 extranodal NK/T-cell lymphoma, nasal type 343  
 follicle center lymphoma 343  
 frequency of specific lymphomas 341, 342  
 $\gamma/\delta$  T-cell lymphoma 343  
 hemophagocytic syndrome 342–343  
 hydroa vacciniforme-like lymphoma 179–181, 179–181, 343  
 intravascular large B-cell lymphoma 344  
 lymphoblastic lymphomas 344  
 lymphomas in immunosuppression 344  
 lymphomatoid granulomatosis 344  
 lymphomatoid papulosis 87, 88, 342  
 marginal zone lymphoma 202, 343–344  
 mycosis fungoides 55–57, 60, 345  
 myelogenous leukemia, cutaneous manifestations 344  
 peripheral T-cell lymphoma NOS 343  
 Sézary syndrome 342  
 subcutaneous panniculitis-like T-cell lymphoma 342–343  
*Chlamydia jejuni* 201  
*Chlamydia psittaci* 201  
 chlorambucil  
 B-cell chronic lymphocytic leukemia 291  
 marginal zone lymphoma 208  
 Sézary syndrome 80  
 chloroma 296  
 chronic actinic dermatitis 353–355  
 chronic discoid lupus erythematosus *see* lupus erythematosus  
 chronic lymphocytic leukemia, B-cell *see* B-cell chronic lymphocytic leukemia (B-CLL)  
 chronic myelogenous leukemia 296, 301  
 cutaneous manifestations *see* myelogenous leukemia classification, EORTC-WHO 4  
 classification, of cutaneous lymphomas 1, 2–3, 4  
 classification, of cutaneous pseudolymphomas 352  
 classification, WHO 2–3  
 clonal dermatoses 351, 357, 413  
 CML *see* myelogenous leukemia  
 CMV infection 11, 265  
 collision tumors 18, 95  
*see also* composite lymphoma  
 composite lymphoma 16, 18, 28, 265, 289, 293, 294, 294  
 contact dermatitis, lymphomatoid *see* lymphomatoid contact dermatitis  
 corticosteroids *see* steroids, intralesional; steroids, local; steroids, systemic  
 Crosti's lymphoma 185, 186, 202, 343  
 clinical features 185, 187  
 cryotherapy 357, 368  
 crystal storing histiocytosis 212, 251, 252  
 crystalloid intracytoplasmic inclusions *see* crystal storing histiocytosis  
 cutaneous and systemic plasmacytosis *see* plasmacytosis  
 cutaneous atypical lymphoid proliferation 351, 413–414, 414  
 cutaneous extramedullary hematopoiesis 394, 394–395  
 cutaneous follicular lymphoid hyperplasia with monotypic plasma cells 201  
 cutaneous IgG4-related disease 386, 387  
 cutaneous inflammatory pseudotumor 388–389, 390  
 cutaneous lymphoma international prognostic index (CLiPi) 61, 80, 195, 208  
 cutaneous lymphoma unclassifiable 413, 414  
 cutaneous NK/T-cell lymphomas 9, 176  
 classification 2–3, 4, 9  
 incidence 9  
*see also* specific lymphomas  
 cutaneous plasmacytosis *see* plasmacytosis  
 cutaneous sarcomatoid B-cell lymphoma 190  
 cutis verticis gyrata 14, 18  
 cyclophosphamide  
 B-cell chronic lymphocytic leukemia 291  
 CD4+ small-medium T-cell lymphoma 166, 167  
 cutaneous plasmacytosis 391  
 cyst, pseudolymphomatous 399  
 cytomegalovirus (CMV) infection 11, 265  
 cytophagic panniculitis 120  
 cytotoxic proteins 133  
 Darier's nests (Pautrier's microabscesses)  
 adult T-cell lymphoma/leukemia 174  
 definition and history 19  
 extranodal NK/T-cell lymphoma, nasal-type 145  
 mycosis fungoides 19, 19, 20, 20, 21, 22, 25, 28, 29, 61, 293  
 lymphomatoid papulosis 91  
 Sézary syndrome 77, 81, 366  
 simulated in  
 diffuse large B-cell lymphoma, leg type 222, 223  
 lichenoid (lymphomatoid) keratosis 357, 358  
 lymphomatoid contact dermatitis 354, 354  
 dendritic cell(s)  
 follicular 191, 192, 382, 384  
 plasmacytoid 126, 207, 207, 376, 376, 377, 377  
 denileukin diftitox 59, 79  
 dermatitis-like infiltrates in malignant disorders  
 extranodal NK/T-cell lymphoma, nasal-type 151–152  
 mycosis fungoides 33, 35, 48  
 myelogenous leukemia 296, 297, 300  
 dermatopathic lymphadenopathy 15, 77  
 diffuse large B-cell lymphoma, EBV+ of elderly  
*see* EBV+ diffuse large B-cell lymphoma of elderly  
 diffuse large B-cell lymphoma, leg type 220–231  
 anaplastic variant 224  
 clinical features 220, 221, 222, 222, 228  
 follicle center lymphoma, diffuse type vs 192, 194, 195, 220, 225, 226–227  
 histopathology 222–224, 223, 224, 228  
 immunophenotype 224, 225, 226, 229  
 molecular genetics 224–225, 226  
 prognosis 226–227  
 spindle cell variant 223  
*see also* spindle cell B-cell lymphoma  
 treatment 226  
 doxorubicin, pegylated liposomal 59  
 drug(s)  
 pseudolymphoma induced by 351–353, 379, 379–380, 380, 381  
*see also individual therapeutic drugs*  
 drug eruptions/reactions  
 erythroderma in 364, 364, 366  
 in leukemias/lymphomas 380  
 lymphomatoid *see* lymphomatoid drug reactions  
 dual-fusion probes 6  
 Dutcher bodies 202, 209, 211  
 cutaneous manifestations of multiple myeloma 251  
 marginal zone lymphoma  
 lymphoplasmacytic variant 210, 211–212, 215  
 plasmacytic variant 212  
 dystrophic calcifications, anaplastic large cell lymphoma 105, 106  
 early malignancy, definition 7–8  
 early summer meningoencephalitis (ESME) 385  
 earring, pseudolymphoma 381  
 EBV *see* Epstein-Barr virus (EBV)  
 EBV+ diffuse large B-cell lymphoma of elderly,  
 cutaneous 245–247  
 classification 245  
 clinical features 245  
 differential diagnosis 282  
 histopathology and immunophenotype 245–246, 246, 247  
 treatment and prognosis 246  
 EBV+ mucocutaneous ulcers 372  
 eczema herpeticum 51  
 elastophagocytosis 205  
 electron beam, total body irradiation *see* total body irradiation  
 endothelial cells  
 angioimmunoblastic T-cell lymphoma 176, 177  
 angiosarcoma, pseudolymphomatous 399, 400  
 arthropod bite reactions 370  
 intralymphatic CD30+ anaplastic large T-cell lymphoma 115, 240  
 intralymphatic histiocytosis 396, 397  
 intravascular large cell lymphomas 232, 235  
 reactive angioendotheliomatosis 235  
 endothelial cells related antibodies 235  
 EORTC *see* European Organization for Research and Treatment of Cancer (EORTC)  
 epidermotropic CD8+ cytotoxic T-cell lymphoma *see* aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma

- epidermotropism
- aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma 134, 135, 136
  - anaplastic large cell lymphoma 102, 103
  - basilar 20, 22
  - cutaneous atypical lymphoid proliferation and disproportionate 20, 22
  - extranodal NK/T-cell lymphoma 145, 146
  - $\gamma/\delta$  T-cell lymphoma, cutaneous 139, 140
  - granulomatous mycosis fungoides and 44
  - lichenoid keratosis 357, 358
  - lichen sclerosus 359, 359
  - lymphomatoid papulosis 91, 92, 93
  - mycosis fungoides 20, 22, 24, 44, 48, 57, 62
    - localized pagetoid reticulosis 46
  - PLEVA 374
  - Sézary syndrome 77
  - see also* Darier's nests (Pautrier's microabscesses)
- epithelial hyperplasia
- anaplastic large cell lymphoma 103–105, 105
  - lymphomatoid papulosis 94, 96
- Epstein-Barr virus (EBV) 6, 7
- aggressive cutaneous cytotoxic lymphomas 133
  - aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma 136
  - aggressive NK cell leukemia 318, 318
  - angiimmunoblastic T-cell lymphoma 176, 177, 178
  - benign and malignant cutaneous lymphoproliferative diseases 7
  - Burkitt lymphoma 252
  - CD4+ small-medium T-cell lymphoma and 164
  - cutaneous lymphomas in HIV infection 275
  - cutaneous lymphomas in immune deficiency disorders 281, 282, 282, 283, 344
  - lymphomatoid granulomatosis 253–256, 255
  - diffuse large B-cell lymphoma, leg type 220
  - EBV+ diffuse large B-cell lymphoma of elderly 245, 246
    - see also* EBV+ diffuse large B-cell lymphoma of elderly
  - EBV+ mucocutaneous ulcer 372
  - extracavitary primary effusion lymphoma, cutaneous manifestations 249, 250
  - extranodal NK/T-cell lymphoma, nasal-type and 144, 146, 147, 147, 150
  - $\gamma/\delta$  T-cell lymphoma, cutaneous and 141
  - Hodgkin lymphoma 331, 333, 334
  - hydroa vacciniforme 373, 374
  - hydroa vacciniforme-like lymphoma 179, 180, 181
  - intralymphatic CD30+ large T-cell lymphoma 239
  - intravascular large B-cell lymphoma 235
  - intravascular large NK/T-cell lymphoma 237, 238
  - lymphomatoid papulosis 94
  - marginal zone lymphoma 202
  - mycosis fungoides 11
  - post-transplant lymphoproliferative disorders 265–274, 372
  - mucocutaneous ulcers associated 372
  - peripheral T-cell lymphoma, NOS 155, 157
  - plasmablastic lymphoma, 256, 257, 258
  - Richter syndrome 291, 291
  - subcutaneous panniculitis-like T-cell lymphoma 124, 124
- eruptive infundibular cysts and comedones 33
- see also* mycosis fungoides, pilotropic (folliculotropic)
- erythema multiforme-like pattern, mycosis fungoides 21, 24
- erythroderma
- actinic reticuloid 366
  - adult T-cell leukemia/lymphoma 172
  - atopic dermatitis 365, 366
  - causes 366
  - classification 74
  - in drug eruptions 364, 364, 366
  - in immunodeficiencies 367, 368
  - lymphomatoid contact dermatitis 354
  - mycosis fungoides 14, 47–48, 51, 74
  - neoplastic 74
  - non-neoplastic in adults 363–366
    - clinical features 364
    - diagnostic problems 366
    - Sézary syndrome vs 74, 364, 366
  - paraneoplastic 366
  - pityriasis rubra pilaris 366
  - pruritic, in Sézary syndrome 74
  - psoriasis 365, 366
  - Sézary syndrome 74, 75, 75, 76, 77, 80, 366
  - T-cell prolymphocytic leukemia 317, 317–318
- erythrodermia pityriasiqae en plaque disseminées 34
- European Organization for Research and Treatment of Cancer (EORTC), cutaneous lymphoma classification 1, 4
- exaggerated arthropod bite-like reaction 287, 288
- histopathology and immunophenotype 290
- extracavitary primary effusion lymphoma, cutaneous manifestations 248–249, 249, 250
- extracorporeal photopheresis
- mycosis fungoides 59
  - Sézary syndrome 79, 81
- extramedullary hematopoiesis, cutaneous 394, 394–395
- extramedullary plasmacytoma 201
- see also* multiple myeloma
- extranodal marginal zone lymphoma of MALT organs
- IgG4 positivity 212
  - immunophenotype 205
  - secondary cutaneous 203
- extranodal NK/T-cell lymphoma, nasal type 143–149
- children/adolescents 343
  - clinical features 144, 144, 150
  - EBV and 147
  - histopathology 145–146, 146, 150
  - immunophenotype 147, 146–147, 150–152, 318
  - molecular genetics 147–148, 148
  - prognosis 148–149
  - secondary 148
  - subcutaneous panniculitis-like T-cell lymphoma vs 125
  - treatment 148
  - see also* lethal midline granuloma
- facial swelling, extranodal NK/T-cell lymphoma 144, 145
- “facies leonina” 287, 353–354, 386
- fat cells, rimming 106, 123, 123, 125, 126, 129, 377, 378
- fludarabine 59, 291
- fluorescent in situ hybridization (FISH) 6
- follicle center lymphoma, cutaneous 183, 185–200
- Borrelia burgdorferi* and 186
  - children/adolescents 343
  - classification 185
  - clinical features 185–187, 186, 187, 196, 197, 198, 202
  - Crosti's lymphoma 185, 186, 187, 197, 202, 343
    - see also* Crosti's lymphoma
  - definition 185
  - differential diagnosis
    - pseudolymphoma at vaccination site vs 384
    - pseudolymphomatous angiosarcoma vs 399
  - diffuse variant 185
- diffuse large B-cell lymphoma, leg type vs 192, 194, 195, 220, 225, 226–227
- early lesions 188, 191, 192
- histopathology 187, 188, 188, 189, 190
- immunophenotype 191, 192, 194
- on legs 195
- T-cell/histiocyte-rich lymphoma relationship 258–259
- follicular variant 185, 189
- histopathology 189, 190
  - immunophenotype 191, 193
- histopathology 187–191, 188, 189, 190, 191, 197, 198
- inversion of follicle architecture 190
  - plasmacytic differentiation 191
  - immunophenotype 191–193, 192
- large cell lymphocytoma 190, 190
- mixed follicular and diffuse type 190, 192
- molecular genetics 193–195
- natural history 196
- prognosis 195
- radiotherapy 186
- spindle-cell variant 190, 191, 191, 343
- see also* spindle cell B-cell lymphoma
- treatment 195
- variants 190–191
- follicular dendritic cells 382, 384
- follicular lymphoid hyperplasia with monotypic plasma cells, cutaneous 201
- follicular lymphoma, nodal 183
- follicular mucinosis 35–41, 42, 56
- acneiform type 39, 41, 43
  - adult T-cell lymphoma/leukemia and 172
  - benign 35–41, 43, 341
  - Hodgkin lymphoma and 331
  - idiopathic generalized 36–37, 38, 42, 49
  - treatment 59
  - mycosis fungoides and 33, 35–41, 36, 37, 38, 40
  - children/adolescents 341
  - Sézary syndrome and 75
- follicular T-helper (T<sub>H1</sub>)-cell lymphoma, cutaneous 9, 167–168
- folliculitis, pseudolymphomatous 398
- folliculotropic mycosis fungoides *see* mycosis fungoides, pilotropic (folliculotropic)
- folliculotropism *see* pilotropism
- $\gamma/\delta$  T-cell lymphoma, cutaneous 120, 137–143
- angiocentricity and angiodestruction 142
  - associated autoimmune disorder 139–140
  - children/adolescents 343
  - classification 137
  - clinical features 138, 138–139, 139, 140
  - cytomorphology 139–140
  - histopathology 139–140, 140, 142, 143
  - immunophenotype 140–141, 143
  - molecular genetics 141–142
  - prognosis 143
  - subcutaneous panniculitis-like T-cell lymphoma vs 125
  - treatment 142
- gemcitabine
- aggressive natural killer cell leukemia 318
  - mycosis fungoides 59
  - Sézary syndrome 80
- gene rearrangement studies 4–5
- see also* immunoglobulin(s); T-cell receptor (TCR)
- genetic investigations 6
- “geographical” lesions, mycosis fungoides 14
- germinal center cell(s)
- follicle center lymphomas 185, 191, 195
  - markers 191, 195

- germinal centers  
 Castleman disease 392, 392  
 lupus panniculitis 377  
 lymphocytoma cutis 381–382, 382  
 mycosis fungoides 28, 32  
 reactive  
 blastic plasmacytoid dendritic cell neoplasms 306, 308  
 follicular colonization 206, 207  
 marginal zone lymphoma, conventional type 204, 204, 206  
 systemic plasmacytosis 389, 391  
ghost cells, subcutaneous panniculitis-like T-cell lymphoma 123, 123  
giant cells, histiocytic, mycosis fungoides variants 46, 48, 49  
glucocorticoids *see* steroids, intralesional; steroids, systemic; steroids, topical  
granulocytic sarcoma *see* myeloid sarcoma  
granuloma annulare 398  
granuloma faciale 386, 387  
granuloma gangrenescens *see* lethal midline granuloma  
granulomatous infiltrate/reaction  
atypical lymphoid proliferations 413  
B-CLL 288  
blastic plasmacytoid dendritic cell neoplasm 306  
CD4+ small–medium T-cell lymphoma 164  
extranodal NK/T-cell lymphoma, nasal type 146  
follicular mycosis fungoides 35, 38  
granulomatous mycosis fungoides 43–44, 45, 47, 48  
granulomatous slack skin 46–47, 49, 50  
lymphomatoid granulomatosis 254  
marginal zone lymphoma 204  
myelogenous leukemia 297, 299  
pilotropic mycosis fungoides 35, 38  
pre-tibial lymphoplasmacytic plaque of children 393, 394  
Sézary syndrome 77  
simulated in anaplastic large cell lymphoma 102–103  
Syphilis 387  
tattoo-associated pseudolymphoma 385  
granulomatous mycosis fungoides *see* mycosis fungoides, granulomatous  
granulomatous slack skin 33, 46–47, 49, 50  
Hodgkin lymphoma association 331  
gumma syphilitica 387  
*see also* syphilis  
  
HAART *see* highly active antiretroviral treatment  
hairy cell leukemia 319  
“haloed” lymphocytes 20, 22, 359  
*Helicobacter pylori* 201  
hemangioma, capillary colonization in intravascular large B-cell lymphoma 232–233, 234  
hematopoiesis, extramedullary 394, 394–395  
hemophagocytic syndrome  
children/adolescents 342–343  
cutaneous  $\gamma/\delta$  T-cell lymphoma 139, 142  
extranodal NK/T-cell lymphoma, nasal type 144  
intravascular large B-cell lymphoma 233  
subcutaneous panniculitis-like T-cell lymphoma 121, 122, 127  
hemophagocytosis *see* hemophagocytic syndrome  
hepatitis C virus (HCV) 186  
“herpes incognito” 371  
herpes simplex infections, pseudolymphoma in 371–372, 372  
herpes zoster, pseudolymphoma in 371–372, 372, 373  
HHV-8 *see* human herpesvirus 8 (HHV-8)  
  
high endothelial venules 176, 177  
highly active antiretroviral treatment (HAART) 277, 367  
hirudo medicinalis therapy and pseudolymphoma 381  
histiocytic cytophagic panniculitis 120  
histiocytoid Sweet’s syndrome 302, 395, 395–396  
histiocytosis  
crystal storing 212, 251  
intralymphatic 396, 396–397, 397  
malignant 120, 138  
regressing atypical 85, 109  
histopathology, general assessment criteria 6  
HIV infection, cutaneous lymphomas 275–280  
anaplastic large cell lymphoma 99–100, 275, 277  
clinical features 275, 278  
histopathology and immunophenotype 275, 276, 277, 278–279  
Hodgkin lymphoma association 331  
mycosis fungoides 275, 277  
plasmablastic lymphoma 256, 258, 275  
pseudolymphomatous cutaneous infiltrates 367, 367  
treatment and prognosis 277  
types of cutaneous lymphoma 275  
Hodgkin cells 332–333, 333  
Hodgkin lymphoma 331–340  
associated lymphoproliferative disorders 331  
classical type, and subtypes 331, 333  
classification 331  
composite with non-Hodgkin lymphoma 289  
cutaneous dissemination and features 99, 331  
in HIV infection 331  
nodular lymphocyte predominant 331  
primary cutaneous 331  
HTLV-I *see* human T-cell lymphotropic virus (HTLV-I)  
HTLV-II 275  
human herpesvirus 8 (HHV-8)  
Castleman disease 392  
cutaneous and systemic plasmacytosis 391  
extracavitary primary effusion lymphoma 248, 249, 250  
follicle center lymphoma and 186  
HIV-related anaplastic large cell lymphoma 275, 277  
mycosis fungoides 11  
plasmablastic lymphoma 256, 258  
human T-cell lymphotropic virus (HTLV-I)  
adult T-cell leukemia/lymphoma 172  
mycosis fungoides and Sézary syndrome 11, 172–173  
post-transplant adult T-cell lymphoma/leukemia 265  
human T-cell lymphotropic virus 2 (HTLV-II) 275  
hydroa vacciniforme 373, 373–374  
hydroa vacciniforme-like lymphoma 133, 176, 179–181  
children/adolescents 343  
clinical features 179, 179, 180  
histopathology and immunophenotype 179, 180, 181  
molecular genetics 180  
treatment and prognosis 180  
hyper eosinophilic syndrome 89  
hyperkeratosis, Sézary syndrome 76  
hyperpigmentation  
lymphomatoid papulosis 90  
mycosis fungoides 50, 54  
hypersensitivity  
delayed, pseudolymphoma after vaccination 385  
to insect bites 179, 287, 373  
  
hypopigmentation  
follicle center lymphoma 186  
follicular mycosis fungoides 38, 42, 341  
mycosis fungoides 33, 49–50, 53, 54, 55, 60, 341  
lymphomatoid papulosis 88, 89  
  
idiopathic generalized follicular mucinosis *see* follicular mucinosis  
idiopathic T-cell pseudolymphoma *see* solitary idiopathic B/T-cell pseudolymphoma  
IgG4  
cutaneous disease related to 386, 387  
marginal zone lymphoma, plasmacytic variant 211–212  
imiquimod  
lymphomatoid papulosis 98  
mycosis fungoides 59  
immune system  
aging, EBV+ diffuse large B-cell lymphoma of elderly 245  
impaired, adult T-cell leukemia/lymphoma 172  
Sézary syndrome 75  
immunocytoma, primary cutaneous 201, 208  
*see also* marginal zone lymphoma, cutaneous  
immunodeficiency  
anaplastic large cell lymphoma 99–100  
congenital 367  
cutaneous lymphoproliferative disorders in 281–286  
clinical features 281  
histopathology and immunophenotype 281–282, 282, 283  
treatment and prognosis 282  
erythroderma in 367, 368  
lobular panniculitis in children 343  
lymphomatoid granulomatosis 281  
pseudolymphomatous cutaneous infiltrates in 367, 367, 368, 378  
*see also* HIV infection, cutaneous lymphomas; post-transplant lymphoproliferative disorders  
immunoglobulin(s)  
class switch 202, 207  
gene rearrangement 5  
light chains *see* immunoglobulin light chains  
immunoglobulin G (IgG), IgG4 *see* IgG4  
immunoglobulin light chains  
double staining for kappa and lambda 206, 206  
monoclonal expression, kappa:lambda diagnostic ratio 206, 206  
immunohistologic analysis, antibodies 5  
immunomodulatory drugs (“biologics”) 60  
immunophenotype 4  
antigen retrieval techniques 4  
monoclonal antibodies 5  
immunosuppressed patients  
cutaneous lymphomas in children/adolescents 344  
cutaneous lymphomas in immunosuppressed individuals 263–264  
HIV infection and lymphomas *see* HIV infection, cutaneous lymphomas  
iatrogenic and non-iatrogenic immune deficiencies 281–284  
post-transplant lymphoproliferative disorders *see* post-transplant lymphoproliferative disorder(s)  
*see also* immunodeficiency  
Indian-filing  
Burkitt lymphoma 252, 253  
cutaneous manifestations of myelogenous leukemia 297, 299  
cutaneous T-lymphoblastic lymphoma 324

- indolent CD8+ lymphoid proliferation of the face/ear  
163, 164, 166–167, 168  
clinical features 167  
histopathology 167, 167
- inflammatory dermatosis-like infiltrates in malignant disorders *see* dermatitis-like infiltrates in malignant disorders
- inflammatory myofibroblastic tumor 389
- inflammatory pseudotumor of skin 388–389, 390
- infundibular cyst, pseudolymphomatous 398
- insect bites, *see* arthropod bite reactions
- interface dermatitis (dermo-epidermal junction)  
extranodal NK/T-cell lymphoma 145, 146  
 $\gamma/\delta$  T-cell lymphoma, cutaneous 138, 139, 139, 140, 141  
lupus panniculitis 377  
mycosis fungoides 21, 48  
subcutaneous panniculitis-like T-cell lymphoma 124
- interferon- $\alpha$   
actinic reticuloid 353  
adult T-cell lymphoma/leukemia 173  
anaplastic large cell lymphoma 109  
angiimmunoblastic T-cell lymphoma 177  
bullous lesions related to in mycosis fungoides 51  
Castleman disease 393  
CD4+ small–medium T-cell lymphoma 166–167  
cutaneous lymphomatoid granulomatosis 256  
diffuse large B-cell lymphoma, leg type 226  
follicle center lymphoma 195  
hairy cell leukemia 319  
hydra vacciniforme-like T-cell lymphoma 180  
lymphocytoma cutis 383  
lymphomatoid granulomatosis 256  
lymphomatoid papulosis 98  
marginal zone lymphoma (conventional variant) 208  
mycosis fungoides 57  
post-transplant lymphoproliferative disorders 268  
Sézary syndrome 79
- intralymphatic CD30+ large T-cell lymphoma 100, 106, 114–115, 232, 237, 239–241  
cases in literature 238  
diagnostic/classification issues 232, 239  
histopathology and immunophenotype 239, 240–241
- intralymphatic histiocytosis 396, 396–398, 397
- intralymphatic proliferation of T-cell lymphoid blasts *see* benign intralymphatic proliferation of T-cell lymphoid blasts
- intranuclear inclusions *see* Dutcher bodies
- intravascular CD30+ large T-cell lymphoma *see* intralymphatic CD30+ large T-cell lymphoma
- intravascular histiocytosis *see* intralymphatic histiocytosis
- intravascular large B-cell lymphoma 223, 232–236  
Asian variant 233  
in B-CLL 289  
children/adolescents 344  
clinical features 233, 233, 234, 242  
colonization of hemangiomas 232–233, 234  
differential diagnosis  
benign intralymphatic proliferation of T-cell lymphoid blasts 397, 398  
intralymphatic histiocytosis vs 396  
reactive angioendotheliomatosis vs 235  
histopathology and immunophenotype 233, 234, 235, 235, 236, 242  
treatment and prognosis 235
- intravascular large cell lymphomas 232–244  
B-cell *see* intravascular large B-cell lymphoma  
CD30+ variant *see* intralymphatic CD30+ large T-cell lymphoma  
NK/T-cell lymphoma  
NK/T-cell variant *see* intravascular large NK/T-cell lymphoma
- intravascular large NK/T-cell lymphoma 232, 237–239  
histopathology and immunophenotype 237, 238  
itching *see* pruritus
- Jessner–Kanof, lymphocytic infiltration 376, 376, 377
- Kaposi sarcoma 220, 233, 256  
kappa:lambda diagnostic ratio 206, 206  
keratoacanthomas, in lymphomatoid papulosis 94, 96  
Ketrion–Goodman type, pagetoid reticulosis 11, 41, 134, 134, 138
- lambda:kappa diagnostic ratio 206, 206
- Langerhans cell(s)  
in mycosis fungoides 21, 27–28, 28, 31  
in lymphomatoid contact dermatitis 354, 354, 355, 403, 403  
in lichenoid (lymphomatoid) keratosis 357, 401, 401
- Langerhans cell microabscesses 28, 31, 354, 401, 403
- large B-cell lymphoma, intravascular *see* intravascular large B-cell lymphoma
- large B-cell lymphoma, leg-type *see* diffuse large B-cell lymphoma, leg-type
- large cell lymphocytoma 190, 190
- large NK/T-cell lymphoma, intravascular *see* intravascular large NK/T-cell lymphoma
- large plaque parapsoriasis *see* parapsoriasis  
leech therapy and pseudolymphoma 381  
*Leishmania* 368, 381  
lentigo actinica 357  
“leonine” face 287, 353, 386  
lethal midline granuloma 143  
clinical features 144, 145
- leukemia  
adult T-cell lymphoma leukemia 172–175, 343  
aleukemic *see* aleukemic leukemia cutis  
blastic plasmacytoid dendritic cell neoplasm 306–316, 344  
B-cell chronic lymphocytic leukemia (B-CLL) 287–295  
composite with other lymphomas 28, 293–294  
drug eruptions, colonization by 380  
lymphoblastic lymphoma/leukemia 320–327, 344  
myelogenous 296–305, 344  
other types 317–319  
Sézary syndrome 74  
transdifferentiation 4  
*see also specific leukemias*
- leukemia cutis *see* leukemia, cutaneous manifestations  
leukemia cutis, aleukemic *see* “aleukemic” leukemia cutis
- leukemia lymphatica mammillae 287, 288
- lichen aureus 357, 359, 359  
relationship with mycosis fungoides 50
- lichenification, pseudolymphomatous atopic dermatitis 362, 363, 363
- lichenoid (lymphomatoid) keratosis 357, 357  
histopathology 357, 358  
solitary idiopathic B/T-cell pseudolymphoma overlap 355, 357
- lichenoid pigmented purpuric dermatitis (lichen aureus) 357, 359, 359
- lichenoid purpuric dermatitis, *see* lichen aureus
- lichen sclerosis 359, 359–360, 360
- lichen simplex chronicus  
in actinic reticuloid 353–354, 366  
in atopic dermatitis 364  
mycosis fungoides simulating 21, 24
- lichen spinulosus 35, 37
- lineage plasticity 185
- lipoatrophic panniculitis of the ankles 379
- lobular panniculitis *see* panniculitis, lobular
- lupus erythematosus  
pseudolymphomas associated 376, 376, 405  
lupus panniculitis *see* lupus panniculitis  
lupus tumidus 376, 376, 377  
other types 379  
subcutaneous panniculitis-like T-cell lymphoma and 120, 122, 125, 377–378  
*see also* Jessner–Kanof
- lupus erythematosus profundus *see* lupus panniculitis
- lupus panniculitis 120, 126, 128, 376–379  
clinical features 376–377, 377  
differential diagnosis 125  
subcutaneous panniculitis-like T-cell lymphoma 125, 377–378  
histopathology 377, 378  
subcutaneous panniculitis-like T-cell lymphoma association 125–126, 126–127, 377–378
- lupus profundus *see* lupus panniculitis
- lupus tumidus 376, 376, 377
- lymphadenosis benigna cutis *see* lymphocytoma cutis
- lymphatic vessels *see* endothelial cells
- lymphoblastic lymphomas, cutaneous 320–325  
B-cell type *see* B-lymphoblastic lymphoma, cutaneous  
children/adolescents 344  
molecular genetics 320  
“null-cell” phenotype 320  
T-cell type *see* T-lymphoblastic lymphoma, cutaneous  
WHO classification 323
- lymphocytes  
angiotropic 26  
“cerebriform” 19, 20, 64, 77  
*see also* Sézary cells  
“haloed” 22, 359  
intraepidermal collections *see* Darier’s nests  
nodular proliferation, in atypical lymphoid proliferation 413  
reactive, marginal zone lymphoma, conventional type 204, 204  
rimming 106, 123, 123, 125, 126, 129, 377, 378  
small reactive, cutaneous follicle center lymphoma 188, 189  
“squared” 223, 224  
superficial infiltrates, in atypical lymphoid proliferation 413
- lymphocytic infiltration of Jessner–Kanof (lupus tumidus) 376, 376, 377
- lymphocytoma cutis 380–383  
antigenic stimuli 381  
*B. burgdorferi*-associated 287, 380–384, 382, 383  
clinical features 381  
drug-induced 381, 381  
earrings 381  
histopathology 381–382, 382, 383  
immunohistology 382, 383  
insect bites 381  
leech therapy 381  
*Leishmania*-associated 381  
tattoos 381  
treatment and prognosis 383
- lymphoepithelial-like carcinoma 399, 399

- lymphoid follicles  
 neoplastic, follicle center lymphoma 188, 189, 189, 190, 190, 192, 192, 193  
*see also* germinal centers
- lymphoma (cutaneous)  
 classification 1, 2–3, 4  
 definition 1  
 examination 1  
 gene rearrangement studies 4–6  
 histopathology 3–4  
 immunophenotype 4, 5  
 investigation methods 6  
 microenvironment 6–7  
 pseudo-/pre-/early malignancy 7–8  
 staging investigations 1, 3  
*see also specific entities*
- lymphoma microenvironment 6–7
- lymphomatoid annular erythema 361
- lymphomatoid contact dermatitis 318, 354, 354–355, 355, 403–404  
 clinical features 354, 355, 403  
 histopathology and immunophenotype 354, 355, 355, 403–404
- lymphomatoid drug reactions 351–352, 379, 379–380, 380, 381  
 B-cell type 380, 381  
 T-cell type 379–380, 380
- lymphomatoid granulomatosis 254  
 cutaneous 254–256  
 children/adolescents 344  
 clinical features 254, 259  
 histopathology, immunophenotype 254, 255, 256  
 treatment and prognosis 256  
 grades 254  
 in immunodeficiencies 281
- lymphomatoid keratosis *see* lichenoid (lymphomatoid) keratosis
- lymphomatoid papulosis 15, 24, 86–99  
 angiodestruction/angiocentricity 88, 89, 93, 111  
 borderline with anaplastic large cell lymphoma 85, 108  
*see also* lymphomatoid papulosis, type C  
 CD56 expression 93, 97  
 children/adolescents 87, 88, 342  
 clinical features 86–89, 87, 88, 89, 90, 91, 110, 112  
 differential diagnosis 97–98  
 anaplastic large cell lymphoma 89, 99–100  
 CD30+ T-cell pseudolymphomas 367–368  
 Hodgkin lymphoma vs 331, 332, 333  
 mycosis fungoides with CD30 infiltration 86, 91  
 PLEVA with CD30+ cells 97, 112–113, 112–113  
 etiology and pathogenesis 86  
 follicular (type F) 94, 95, 96  
 histological variants 94–95  
 histopathology 89–95, 91, 92, 93, 95, 96, 110, 111, 112–113  
 immunophenotype 91, 92, 93, 94, 95, 95, 96, 97, 97, 111, 111, 112, 112, 113  
 keratoacanthomas with 94, 96, 103  
 lethal midline granuloma with 144  
 lymphomas associated 86, 99, 342  
 molecular genetics 97  
 “persistent agmination” 89  
 prognosis 98–99  
 “progression” 100  
 PUVA-induced 24, 86  
 regional 89, 91  
 anaplastic large cell lymphoma vs 109  
 primary cutaneous Hodgkin lymphoma vs 335  
 small cell variant 91–92  
 syringotropic 94, 96  
 treatment 98  
 type A (conventional/histiocytic) 90–91, 91, 94  
 type B (mycosis fungoides-like) 91–92, 92, 95  
 type C (anaplastic large cell lymphoma-like) 86, 92, 93  
 type D (cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma-like) 92, 93, 94, 97  
 differential diagnosis 134  
 type E (angiocentric/angiodestructive) 93–94, 95  
 lymphoplasmacytic lymphoma, WHO classification 202  
 lymphoplasmacytic plaque in children, *see* pre-tibial lymphoplasmacytic plaque in children  
 lymphoplasmacytoid cells, marginal zone lymphoma, lymphoplasmacytic variant 208, 209  
 lymphoproliferative disorders, post-transplant *see* post-transplant lymphoproliferative disorders
- macrophages, tingible body 381, 382, 383  
*see also* germinal centers
- macrophage activating syndrome 343
- malignant angioendothelomatosis 232
- malignant histiocytosis 120, 138
- “malignant syphilis” 387
- MALT-lymphoma  
 cutaneous *see* marginal zone lymphoma (cutaneous)  
 follicle center lymphoma vs 191  
*see also* extranodal marginal zone lymphoma of MALT organs
- mantle cell lymphoma, cutaneous 247–248  
 clinical features 247, 247  
 histopathology, immunophenotype 247, 248, 249  
 treatment and prognosis 248
- marginal zone cells  
 blastoid 204–205, 205  
 marginal zone lymphoma, conventional type 204, 205
- marginal zone lymphoma (cutaneous) 183, 201–219  
 autoimmune disorders and 202  
 blastoid variant 213–215  
 clinical features 214  
 histopathology 214, 214  
 immunophenotype 214  
 molecular genetics 214  
 treatment and prognosis 215  
 children/adolescents 343–344  
 clinical features  
 conventional type 202–208  
 clinical features 202–203, 203  
 histopathology 203–205, 204, 205, 206  
 immunophenotype 205–207  
 lymphoplasmacytic variant vs 201–202, 209  
 microorganisms associated 202, 208  
 molecular genetics 207–208  
 prognosis 208  
 treatment 208–209  
 cutaneous atypical lymphoid proliferation and 413  
 epidermotropic 202  
 histopathological presentations 201  
 lymphoplasmacytic variant 208–211  
*Borrelia burgdorferi* association 202, 209, 210  
 clinical features 209, 209, 210, 215  
 conventional type vs 201–202, 209  
 histopathology 209, 210  
 immunophenotype 210, 215  
 molecular genetics 210  
 prognosis 211  
 treatment 210  
 microorganisms associated 202, 208, 209, 210  
 mycosis fungoides with 202  
 plasmacytic variant 211–213  
 clinical features 212  
 histopathology 212, 212, 213  
 immunophenotype 212–213, 213  
 molecular genetics 213  
 treatment and prognosis 213  
 splenic and extranodal MALT-type 201
- mature B-cell neoplasms, transdifferentiation 4  
*see also* transdifferentiation
- melanocytic nevi and mycosis fungoides 16, 19
- melanoerythroderma  
 mycosis fungoides 50  
 Sézary syndrome 75, 76  
*see also* erythroderma
- melanoma and mycosis fungoides 16
- meningoencephalitis, early summer (ESME) 385
- Merkel cell carcinoma 323
- Merkel cell polyoma virus (MCPyV) 186
- methotrexate  
 anaplastic large cell lymphoma 109  
 blastic plasmacytoid dendritic cell neoplasm 311  
 intravascular large B-cell lymphoma 235  
 lymphomas associated 281–282, 282  
 lymphomatoid papulosis 98  
 mycosis fungoides 58, 59  
 pityriasis lichenoides et varioliformis acuta, ulcero-necrotic variant 374  
 psoriasis 366  
 Sézary syndrome 79  
 subcutaneous panniculitis-like T-cell lymphoma 127  
 T-cell large granular lymphocytic leukemia 319  
 microenvironment 6  
 microorganisms, lymphoma-associated 6–7  
 follicle center lymphoma 186–187  
 marginal zone lymphoma 202, 208, 209, 210  
 mycosis fungoides association 11  
*see also Borrelia burgdorferi*; Epstein–Barr virus (EBV); *other specific microorganisms*
- micro RNA (miRNA)  
 anaplastic large cell lymphoma 108  
 mycosis fungoides 32  
 Sézary syndrome 79
- milia en plaques 36, 40
- milker’s nodule 368, 369  
 anaplastic large cell lymphoma mimicking 100, 101
- molecular genetic investigations 6
- molluscum contagiosum 368
- monoclonal antibodies *see* immunophenotype
- monoclonal antibody immunomodulator-related lymphoid proliferations 281
- monoclonal gammopathy of undetermined significance (MGUS) 7
- monocytoid cells, atypical, in myelogenous leukemia 297, 298
- monomorphic post-transplant lymphoproliferative disorder *see* post-transplant lymphoproliferative disorders
- morphea 386, 387
- “mosaic stone” patterns  
 B-lymphoblastic lymphoma 320, 321  
 Burkitt lymphoma 252, 253  
 diffuse large B-cell lymphoma 223, 224  
 Mucha–Habermann disease *see* pityriasis lichenoides and varioliformis acuta (PLEVA)
- mucin deposition  
 mycosis fungoides 35–36, 36, 37, 38  
*see also* follicular mucinosis

- mucocutaneous ulcers, EBV-associated *see* EBV+ mucocutaneous ulcers
- multiple myeloma, cutaneous manifestations 250–252  
 clinical features 250, 251  
 histopathology and immunophenotype 250–252, 251, 252  
 treatment and prognosis 252
- mycosis fungoides 11–73  
 acanthosis nigricans-like 33, 54–55  
 adnexotropic 41  
 adult T-cell leukemia/lymphoma similarity 172  
 agminated lesions 35, 37  
 Alibert–Bazin type 11  
 anetodermic 33, 51–52, 58  
 angiocentricity and angiotropism 22, 26  
 associated conditions 11, 15  
 anaplastic large cell lymphoma 15–16  
 B-CLL 28, 289, 293–294  
 cancers and non-Hodgkin's lymphomas 16, 28  
 collision tumors 18  
 composite lymphoma 16, 18, 289, 293–294  
 HIV infection 275, 277  
 Hodgkin lymphoma 11, 15  
 in patients taking immunomodulatory drugs 60  
 immunosuppression 281  
 lymphomatoid papulosis 11, 15, 86  
 melanocytic nevi 16, 19  
 melanoma 16  
 seborrheic keratosis 16  
 second malignancies 11, 16, 18, 46  
 “a tumeur d'emblée” 11, 43, 134, 138  
 bullous (vesiculobullous) 33, 51, 56, 57  
 children/adolescents 55–57, 60, 341–342, 345  
 classification 4, 11–12  
 variants 33–55, 33  
 clinical features 4–65  
 clinical/histopathologic variants 33, 33–55  
 children/adolescents 55–57, 60, 341–342, 345  
 composite lymphoma 16, 18, 28, 289, 293–294  
 cytotoxic 30, 33  
 dark skin 13–14, 17  
 definition 11, 13, 18–19  
 diagnosis 19–20  
 differential diagnosis  
 acrodermatitis chronica atrophicans, pseudolymphomatous 362  
 actinic reticuloid 352–353  
 annular lichenoid dermatitis of youth 361  
 atopic dermatitis, pseudolymphomatous 363  
 CD4+ small–medium T-cell lymphomas 163  
 children/adolescents 341  
 cutaneous  $\gamma/\delta$  T-cell lymphoma 139  
 extranodal NK/T-cell lymphoma 144  
 in hypopigmented mycosis fungoides 49  
 inflammatory diseases 31, 32–33, 35, 60  
 lichen aureus 357, 359  
 lymphomatoid contact dermatitis 354  
 lymphomatoid drug reactions 379–380  
 solitary idiopathic B/T-cell pseudolymphoma 355–356, 401–402  
 subcutaneous panniculitis-like T-cell lymphoma 125  
 syphilis, pseudolymphomatous 387  
 digitated patches 34, 35  
 dyshidrotic 33, 51, 57  
 early  
 diagnosis 4  
 histological criteria for diagnosis 19, 20  
 histopathology 20, 21–23, 28, 33  
 with eruptive cysts and comedones 36, 40, 41  
 erythrodermic 33, 47–48, 51, 74  
 etiology 11  
 extracutaneous involvement 14–15  
 folliculotropic *see* mycosis fungoides, pilotropic  
 follicular mucinosis in 33, 35–41, 36, 37, 38, 40  
 children/adolescents 341  
 genetic factors 11  
 granulomatous 33, 43–45, 47, 48  
 prognosis 45  
 granulomatous slack skin *see* granulomatous slack skin  
 histopathologic criteria for diagnosis 20  
 histopathologic differential diagnosis 32–33  
*see also* mycosis fungoides, differential diagnosis  
 histopathological variants 33  
*see also* specific variants  
 histopathology 18–20, 19–27, 20–24, 32, 36–58, 62, 63–66, 293–294, 345–346  
 early stage 20–21, 20–24, 345–346  
 intraepidermal lymphocytes 19, 19, 20, 20, 21, 22, 23  
 large cell transformation 22–25, 27, 60, 63, 86  
 plaque stage 21, 25  
 tumor stage 21–22, 26  
 historical terms/synonyms 33–34, 34  
 hyperkeratotic 33  
 hyperpigmented 33, 50, 54  
 hypopigmented 13, 33, 49–50, 53, 54, 55, 60  
 children/adolescents 341  
 ichthyosiform 33, 54, 59  
 immunomodulatory drugs, association with use of 60  
 immunophenotype 25–28, 28–31, 293–294, 345–346  
 B-cell reaction 28, 32  
 incidence 11  
 interstitial 22, 33, 48, 52  
 invisible 33, 52, 54  
 large cell transformation *see* mycosis fungoides, transformation, large cell  
 lichenoid type 48  
 lichen simplex chronicus-like 21, 24  
 localized pagetoid reticulosis (Woringer–Kolopp type) 33, 41–42, 46, 47, 55, 341  
 lymph node involvement 15  
 marginal zone lymphoma with 202  
 microorganisms associated 11  
 molecular genetics 28, 31–32  
 mucosal region involvement 14, 19  
 pagetoid reticulosis 33, 33, 41–42, 46, 47, 55, 341  
 palmaris et plantaris 33, 54  
 papular 50, 55, 56  
 papuloerythroderma Ofuji 33  
 parapsoriasis *see* parapsoriasis  
 patch stage 13, 14, 15, 32  
 perioral dermatitis-like 33, 54, 59  
 pigmented purpura-like 33, 50, 55  
 pilotropic (folliculotropic) 12, 33, 35–41, 35, 36, 37, 38, 39, 40, 42, 56  
 hypopigmentation 38, 42  
 prognosis 38  
 treatment 59  
 plaque stage 13–14, 16, 26  
 histology 21, 25  
 PLEVA-like 33, 52, 56, 58, 341, 374  
 children/adolescents 341, 344–345, 345  
 evolution into mycosis fungoides 374  
 poikilodermatous 13, 33, 48, 53  
 histopathology 21  
 post-transplant lymphoproliferative disease 265, 268  
 prognosis 11, 26, 60–61, 63  
 purpuric 33, 50, 55  
 pustular 33  
 quality of life 59–60  
 rapidly progressive 11  
 regression 16, 23  
 Sézary syndrome overlap 47, 77  
 Sézary syndrome relationship 13, 74, 77  
 skin of colour 13–14, 17  
 solitary (unilesional) 33, 43, 47, 63, 356  
 staging 11, 12  
 syringotropic 33, 41, 44, 45  
 treatment 59  
 T-follicular helper cells 25, 33  
 T-regulatory cells 27, 30, 33  
 transformation, large cell 22–25, 27, 33, 60, 63, 86  
 treatment 57–60  
 tumeur d'emblée 11, 43, 134, 138  
 tumor stage 14, 16, 17, 18, 19, 26, 42  
 cytotoxic phenotype 26  
 histopathology 21–22, 26  
 immunophenotype 30  
 unilesional (solitary) 33, 43, 47, 63, 356  
 variants 33–55, 33  
*see also* specific variants  
 verrucous/hyperkeratotic 33  
 vesiculo-bullous *see* mycosis fungoides, bullous  
 zosteriform 33  
 mycotic infections, pseudolymphoma 368, 370  
 myelodysplastic syndromes, cutaneous manifestations 296, 302, 302  
 myelogenous leukemia  
 blastic plasmacytoid dendritic cell neoplasms relationship 306  
 Sweet syndrome and 395  
*see also* myelogenous leukemia, cutaneous manifestations  
 myelogenous leukemia, cutaneous manifestations 287, 296–305  
 children/adolescents 344  
 blastic plasmacytoid dendritic cell neoplasm vs 310  
 clinical features 296, 297, 303  
 cutaneous B-lymphoblastic lymphoma vs 322  
 cutaneous extramedullary hematopoiesis vs 394  
 histopathology 297–298, 298, 303  
 immunophenotype 298–299, 300, 301, 304  
 molecular genetics 300  
 “smoldering” form 302  
 treatment and prognosis 300–301  
 WHO classification 296  
 myeloid precursors, markers 394  
 myeloid leukemia *see* myelogenous leukemia  
 myeloid sarcoma 296  
 histopathology 298, 301  
 myeloma *see* multiple myeloma  
 myofibroblastic tumor, inflammatory 389  
 nail dystrophy, Sézary syndrome 76  
 nasal type, extranodal NK/T-cell lymphoma *see* extranodal NK/T-cell lymphoma, nasal-type  
 natural killer (NK) cell(s), lymphomas *see* cutaneous NK/T-cell lymphomas  
 natural killer (NK) cell leukemia, aggressive 318, 318  
 neoplastic ulcers 220, 221  
 neuroendocrine carcinoma, metastatic 323  
 next generation sequencing 6  
 NK/T-cell lymphoma, nasal-type *see* extranodal NK/T-cell lymphoma, nasal-type



- nodal follicular lymphomas 183  
 comparison with cutaneous follicle center lymphoma 185, 194
- nodular arthropod bite reactions, persistent 155, 369–371, 370, 371
- nodular scabies 369–371, 370, 371
- non-neoplastic erythroderma in adults *see* erythroderma
- Ofuji, papuloerythroderma 33, 55
- Ontak® 59, 79
- orf 368  
 anaplastic large cell lymphoma vs 100, 101
- organ transplantation, lymphoproliferative disorders *see* post-transplant lymphoproliferative disorder(s)
- overdiagnosis in cancer 7
- pagetoid reticulosis 4  
 generalized (Ketrone–Goodman type) 11, 41, 134, 134, 138  
 localized (Woringer–Kolopp type) 33, 33, 41–42, 46, 47, 55, 341
- palisading granuloma-like pattern in anaplastic large cell lymphoma 102, 103
- panniculitic T-cell dyscrasia 120
- panniculitis  
 benign 121  
 histiocytic cytophagic 120  
 lipotrophic panniculitis of the ankles 379  
 lobular, children/adolescents 343  
 lupus *see* lupus panniculitis  
 Weber–Christian 120
- panobinostat 59
- papuloerythroderma Ofuji 33, 55
- parakeratosis variegata 34, 34, 48
- parapsoriasis 13, 33, 34–35, 49  
 large plaque 34, 34–35  
 relationship to mycosis fungoides 34  
 small plaque 9, 34–35, 35
- parapsoriasis lichenoides 34
- parapsoriasis variegata 34
- parvovirus B19 374
- Pautrier's microabscesses *see* Darier's nests (Pautrier's microabscesses)
- pegylated liposomal doxorubicin 59
- peripheral T-cell lymphoma NOS, cutaneous 155–162  
 CD4+ small–medium T-cell lymphomas vs 168  
 children/adolescents 343  
 classification 155  
 clinical features 155, 156, 157, 160  
 histopathology 156, 157, 158, 160  
 immunophenotype 157, 158, 160, 161  
 molecular genetics 157  
 prognosis 157–158  
 treatment 157
- pernio, pseudolymphomatous 398
- persistent nodular arthropod bite reactions 155, 369–371, 370, 371
- photodynamic therapy 59
- photopheresis, extracorporeal *see* extracorporeal photopheresis
- photosensitivity 77, 179, 353, 366, 373
- pigmented purpura 50, 55  
*see also* lichen aureus
- pigment incontinence, 21, 48, 50, 366
- pilotropic mycosis fungoides  
*see* mycosis fungoides, pilotropic (folliculotropic)
- pilotropic T-cell dyscrasia 36–37
- pilotropism 3  
 lymphomatoid papulosis 94, 95, 96  
 mycosis fungoides *see* mycosis fungoides, pilotropic, *and* mycosis fungoides, syringotropic
- pseudolymphoma in HIV-patients 367
- pityriasis lichenoides and varioliformis acuta (PLEVA) 21, 97, 374–375, 374–375  
 atypical 374, 375  
 with CD30+ cells 374, 376  
 atypical CD30+ cells 97  
 lymphomatoid papulosis vs 97, 112–113, 112–113  
 clinical features 374  
 febrile ulceronecrotic type 374, 374, 375  
 immunophenotype 374–375, 376  
 mycosis fungoides, association *see* mycosis fungoides, PLEVA-like  
 parvovirus B19 97, 374  
 viral etiology 374
- pityriasis lichenoides and varioliformis acuta (PLEVA)-like mycosis fungoides *see* mycosis fungoides, PLEVA-like
- pityriasis rubra pilaris, erythroderma in 366
- placebo treatment 58, 59
- plasmablast(s) 250, 256–258, 257
- plasmablastic lymphoma, cutaneous 7, 256–258, 257  
 clinical features 275  
 in HIV infection 256, 275  
 in immune suppressed individuals 266, 272–273  
 progression to in Castleman disease 392
- plasma cells, kappa:lambda diagnostic ratio 206, 206
- plasma cell granuloma, cutaneous 388–389, 390
- plasmacytic hyperplasia, in post-transplant lymphoproliferative disorders 3, 265, 268
- plasmacytoid cells, marginal zone lymphoma 204, 207, 207
- plasmacytoid dendritic cell neoplasm, blastic *see* blastic plasmacytoid dendritic cell neoplasm
- plasmacytoid type 2 dendritic cell 306
- plasmacytoma 271  
 extramedullary 201  
 post-transplant 266  
 primary cutaneous *see* marginal zone lymphoma (cutaneous), plasmacytic variant  
*see also* multiple myeloma, specific cutaneous manifestations
- plasmacytosis  
 cutaneous 389, 391, 391, 392  
 solitary cutaneous 393  
*see also* pre-tibial lymphoplasmacytic plaque in children  
 systemic 389, 391
- plasticity of cells 4
- pleomorphic small–medium T-cell lymphoma *see* CD4+ small–medium T-cell lymphoma, cutaneous
- PLEVA *see* pityriasis lichenoides and varioliformis acuta (PLEVA)
- poikiloderma vasculare atrophicans 33, 34, 48  
*see also* mycosis fungoides, poikilodermatous
- polymorphic post-transplant lymphoproliferative disorder *see* post-transplant lymphoproliferative disorders
- post-transplant lymphoproliferative disorders 3, 7, 265–274  
 classification/categories 265  
 B-cell lymphoma 266  
 clinical features 265, 266, 272  
 early lesions 265  
 extracutaneous 265, 266  
 histopathology and immunophenotype 265–266, 267, 268, 269, 272, 273
- Hodgkin lymphoma 265  
 molecular genetics 266  
 monomorphic lesions 265, 266, 266, 269, 270  
 mycosis fungoides 265  
 plasmablastic lymphoma 256–258  
 plasmacytoma 266  
 polymorphic lesions 265, 266, 267, 268  
 risk factors 265  
 T-cell lymphoma 266  
 treatment and prognosis 268
- post-transplant lymphoproliferative disorder-like polymorphic infiltrate, in HIV infection 275
- precursor B-lymphoblastic lymphoma *see* B-lymphoblastic lymphoma, cutaneous
- precursor T-lymphoblastic lymphoma *see* T-lymphoblastic lymphoma, cutaneous
- pre-malignancy 7–8
- premycotic erythema 34
- prereticulotic poikiloderma 34
- pre-tibial lymphoplasmacytic plaque in children 393, 393–394
- “primary cutaneous Hodgkin lymphoma” 85, 331, 332, 335–336
- primary cutaneous lymphoma, classification 1, 4
- primary effusion lymphoma *see* extracavitary primary effusion lymphoma
- proliferation centers, in B-CLL 288, 289
- pruritus  
 actinic reticuloid 353, 366  
 atopic dermatitis 362  
 erythroderma 366, 366  
 Hodgkin lymphoma 331  
 mycosis fungoides 14, 35, 39, 59, 60  
 Sézary syndrome 75  
 “pruritus sine materia” 331
- pseudoocularity 6, 351
- pseudoepitheliomatous hyperplasia, epidermis  
 anaplastic large cell lymphoma 103–104, 105  
 lymphomatoid papulosis 94, 96
- pseudo-Hodgkin disease 85
- pseudolymphoma 341, 351–412, 352  
 “accidental” 351, 398  
 in B-CLL 287  
 CD30+ T-cell 367–368, 368  
 classification 352  
 in congenital immunodeficiency 367, 368, 378  
 cutaneous atypical lymphoid proliferation and 413  
 drug reactions 379, 379–380, 380  
 follicular, after vaccines 384, 384–385, 385  
 in herpes simplex infections 371–372, 372  
 in herpes zoster 371–372, 372, 373  
 histological diagnostic criteria 351  
 in HIV infection 367, 367  
 lupus erythematosus association 376, 376, 405  
 “malignant” 399  
 in syphilis 386–388, 388, 389, 390  
 T- and B-cell variants 351–353  
 in tattoos 385, 386  
 terminology and implications 351  
 at vaccination sites 384, 384–385, 385  
*see also specific types (as listed on page 352)*
- pseudolymphoma of Spiegler–Fendt *see* lymphocytoma cutis
- pseudolymphomatous acrodermatitis chronica atrophicans 361–362, 362
- pseudolymphomatous angiosarcoma 399, 400
- pseudolymphomatous angiokeratoma *see* acral pseudolymphomatous angiokeratoma in children (APACHE)
- pseudolymphomatous atopic dermatitis 362–363, 363, 364
- pseudolymphomatous trichophytia 368, 370

- pseudomalignancy 7–8  
 psoralens with UV-A irradiation *see* PUVA  
 psoriasis, erythroderma in 365, 366  
 purpura  
   in angioimmunoblastic T-cell lymphoma 176  
   in Castleman disease 392  
   in intravascular large cell lymphomas 233  
   in mycosis fungoides 21, 42, 57  
   in myelogenous leukemia 297  
   in Sézary syndrome 81  
   *see also* lichen aureus
- PUVA  
 actinic reticuloid 353, 355  
 adult T-cell leukemia/lymphoma 173, 174  
 atopic dermatitis, pseudolymphomatous 363  
 hydroa vacciniforme 374  
 lichen aureus 357  
 lymphomatoid papulosis 86, 98  
 mycosis fungoides 24, 42, 57, 58, 59, 61  
 plasmacytosis, cutaneous 391  
 pseudolymphomatous infiltrates in  
   immunodeficiencies 367  
 Sézary syndrome 80, 81  
*see also* bath-PUVA
- radiotherapy  
 anaplastic large cell lymphoma, cutaneous  
   106–109  
 B-cell chronic lymphocytic leukemia 291, 292  
 CD4+ small/medium T-cell lymphoma 166, 167  
 Diffuse large B-cell lymphoma, leg-type 226, 227  
 extranodal NK/T-cell lymphoma, nasal-type 148,  
   149  
 follicle center lymphoma 185–186, 187, 195, 196,  
   197  
 Hodgkin lymphoma, cutaneous 333, 334  
 immune deficiency-associated cutaneous  
   lymphomas 268, 270, 277, 277  
 intralymphatic histiocytosis 398  
 lymphocytoma cutis 383  
 lymphomatoid papulosis 98  
 marginal zone lymphoma 208, 208, 210, 210, 212  
 multiple myeloma, cutaneous manifestations 252,  
   252  
 mycosis fungoides 42, 59  
 subcutaneous panniculitis-like T-cell lymphoma  
   127  
 tattoo, pseudolymphomatous 385  
 T-cell/histiocyte-rich B-cell lymphoma 259  
 total body *see* total body irradiation  
 reactions to arthropod bites *see* arthropod bite  
   reactions  
 reactive angioendotheliomatosis *see*  
   angioendotheliomatosis, reactive  
 “red man syndrome” 366  
   *see also* erythroderma  
 Reed–Sternberg cells 332–333, 333  
 regressing atypical histiocytosis 85, 109  
 rete ridges, “squaring” 361, 362  
 reticulohistiocytoma of the back/dorsum *see* Crosti’s  
   lymphoma  
 retiform type of parapsoriasis 34  
 retinoids  
   adult T-cell lymphoma/leukemia 173  
   anaplastic large cell lymphoma, cutaneous 109  
   lymphomatoid papulosis 98  
   mycosis fungoides 57, 58–59  
   Sézary syndrome 80
- rhythmic paradoxical eruption 86  
 Richter syndrome 291, 291  
   *see also* B-cell chronic lymphocytic leukemia  
   (B-CLL), cutaneous manifestations
- rimming of adipocytes 106, 123, 123, 125, 126, 129,  
 377, 378
- rituximab  
 B-CLL 291  
 diffuse large B-cell lymphoma, leg type 226  
 EBV+ diffuse large B-cell lymphoma of elderly  
   247  
 exacerbation of lymphomatoid papulosis under  
   treatment with 86  
 follicle center lymphoma 195  
 hairy cell leukemia 319  
 immune deficiency-associated lymphoproliferative  
   disorders 284  
 intravascular large B-cell lymphoma 235  
 lymphomatoid granulomatosis 256  
 marginal zone lymphoma  
   transformation to plasmacytic type after  
   treatment with 201  
   treatment 208  
 post-transplant lymphoproliferative disorders 268  
 romidepsin, mycosis fungoides 59  
 Russel bodies 212, 213, 214, 251
- sarcomatoid B-cell lymphoma 190  
 scabies, nodular 369–371, 370, 371  
 scleroderma, pseudolymphomatous 386, 387  
 seborrheic keratosis  
   colonization of in mycosis fungoides 16  
   related to lichenoid (lymphomatoid) keratosis  
   357  
 second malignancy risk 11, 16, 18, 46, 86  
 secondary syphilis *see* syphilis, pseudolymphomatous  
 Sézary cells 12, 47, 74, 75, 77, 79, 80  
 disorders with 366  
 in actinic reticuloid 353  
 number, Sézary syndrome diagnosis 74  
 Sézary syndrome 74–84  
 children/adolescents 342  
 classification and staging 12, 74–75  
 clinical features 75, 75–76, 76, 81  
 diagnostic criteria 74, 77  
 differential diagnosis 74  
   actinic reticuloid 353  
   non-neoplastic erythroderma in adults 364, 366,  
   366  
   T-cell prolymphocytic leukemia 317, 318  
 erythroderma 74, 75, 75, 76, 77, 80, 366  
 etiology/pathogenesis 75  
 follicular mucinosis and 75  
 histopathology 77, 78, 79, 81  
 HTLV-1 infection and 172–173  
 immune response changes 75  
 immunophenotype 77, 79  
 lymph node enlargement 75, 75, 77  
 melanoerythroderma 75, 76  
 molecular genetics 79  
 mycosis fungoides overlap 47  
 mycosis fungoides relationship 13, 74, 77  
 prognosis 77, 80  
 purpura on palms 81  
 staging 12  
 treatment 79–80  
 variants 75–76, 77
- Sister Mary Joseph’s nodule 247  
 “skin of color” 13–14, 17  
 slack skin, granulomatous *see* granulomatous slack  
 skin  
 small B-cell lymphoma with plasmacytic differentiation  
   202  
 small–medium pleomorphic T-cell lymphoma *see*  
   CD4+ small–medium T-cell lymphoma,  
   cutaneous
- small–medium pleomorphic T-cell nodule of  
 undetermined significance 163, 168  
*see also* CD4+ small–medium T-cell lymphoma,  
 cutaneous  
 small–medium T-cell lymphoma *see* CD4+  
 small–medium T-cell lymphoma, cutaneous  
 small papular pseudolymphoma 356  
 small-plaque parapsoriasis *see* parapsoriasis  
 solitary cutaneous plasmacytosis 393  
 solitary idiopathic B/T-cell pseudolymphoma 351,  
   355–357  
   clinical features 355, 355, 401  
   histopathology 355–356, 356, 402  
   lichenoid keratosis overlap 355, 357  
   patterns 355–356  
 solitary mycosis fungoides *see* mycosis fungoides,  
 solitary  
 solitary T-cell pseudolymphoma *see* solitary idiopathic  
 B/T-cell pseudolymphoma  
 Spiegel–Fendt, pseudolymphoma of *see*  
 lymphocytoma cutis  
 spindle cell B-cell lymphoma  
   diffuse large B-cell lymphoma, leg type 223  
   follicle center lymphoma 190, 191, 191, 343  
 spindle cells *see* spindle cell B-cell lymphoma  
 spongiosis  
   aggressive epidermotropic CD8+ cytotoxic T-cell  
   lymphoma 134  
   atopic dermatitis 363, 366  
   hydroa vacciniforme-like lymphoma 179  
   lymphomatoid contact dermatitis 354, 354, 403  
   mycosis fungoides 20, 21, 21, 22, 23, 51  
   persistent arthropod bite reactions 370  
   Sézary syndrome 77, 78
- squamous cell carcinoma  
 lymphoepithelial-like *see* lymphoepithelial-like  
 carcinoma  
 pseudocarcinomatous hyperplasia in anaplastic large  
 cell lymphoma 105, 105
- staging investigations 1, 3  
 anaplastic large cell lymphoma 99, 99  
 atypical lymphoid proliferations 414  
 B-cell lymphomas 183  
 diffuse large B-cell lymphoma, leg-type 220  
 follicle center lymphoma 185  
 lymphomatoid papulosis 86  
 marginal zone lymphoma 203  
 mycosis fungoides 11, 12, 13  
 peripheral T-cell lymphoma, NOS 155  
 Sézary syndrome 74  
 “starry sky” pattern  
   B-lymphoblastic lymphoma 320, 321  
   Burkitt lymphoma 252, 253  
   diffuse large B-cell lymphoma, leg type 223  
   lymphoblastic lymphomas 320  
   lymphocytoma cutis 383  
   myelogenous leukemia 303  
   T-lymphoblastic lymphoma 324
- stem cell transplantation  
 adult T-cell lymphoma/leukemia 173  
 blastic plasmacytoid dendritic cell neoplasm 311,  
   313  
 B-lymphoblastic lymphoma 323  
 extranodal NK/T-cell lymphoma 148  
 intravascular large cell lymphoma 235  
 lymphomatoid granulomatosis 256  
 mantle cell lymphoma 248  
 mycosis fungoides 59  
 myelogenous leukemia 301  
 Sézary syndrome 80  
 T-cell prolymphocytic leukemia 317, 318  
 T-lymphoblastic lymphoma 325

- steroids, intralesional  
 cutaneous and systemic plasmacytosis 391  
 lymphocytoma cutis 383  
 nodular scabies 371  
 pre-tibial lymphoplasmacytic plaque in children 394  
 pseudolymphoma in tattoo 385
- steroids, local  
 intralymphatic histiocytosis 397  
 lichen aureus 357  
 lymphomatoid papulosis 98  
 mycosis fungoides 57  
 pagetoid reticulosis, localized 42
- steroids, systemic  
 actinic reticuloid 353  
 angioimmunoblastic T-cell lymphoma 179  
 Castleman disease 393  
 Histiocytoid Sweet syndrome 396  
 IgG4-related disease 386  
 marginal zone lymphoma 208  
 pseudolymphomas in HIV patients 367  
 pseudolymphomas in lupus erythematosus 379  
 psoriasis 366  
 subcutaneous panniculitis-like T-cell lymphoma 127  
 T-cell large granular lymphocytic leukemia 319  
 subcutaneous anaplastic large cell lymphoma 125  
 subcutaneous panniculitis-like T-cell lymphoma 7, 120–132, 136, 266, 342–343, 413  
 associated disorders  
 autoimmune disorders 120, 122, 125  
 lupus erythematosus 120, 122, 125  
 lupus panniculitis 125–126, 126–127, 128, 129  
 T- and B-cell lymphomas 120  
 children/adolescents 342–343  
 clinical features 121, 121–122, 122, 128  
 definition and diagnostic criteria problems 120  
 differential diagnosis 125, 343  
 cutaneous NK/T-cell lymphomas with subcutaneous tissue involvement 125  
 $\gamma/\delta$  T-cell lymphoma, cutaneous 138, 139  
 lupus panniculitis 125, 377–378  
 panniculitis in children with immune deficiencies 367  
 pseudolymphomatous infiltrates in immunodeficiency 367  
 etiology and pathogenesis 120  
 hemophagocytic syndrome in 122, 127  
 histopathology 122, 122–124, 123, 124, 126–130  
 immunohistology 124, 124, 126–130  
 molecular genetics 125  
 post-transplant 266  
 prognosis 127  
 treatment 125
- surgical techniques 3  
 surgical treatment 3  
 anaplastic large cell lymphoma 108  
 B-cell chronic lymphocytic leukemia 291  
 CD4+ small-medium T-cell lymphoma 166  
 CD30+ T-cell pseudolymphomas 368  
 follicle center lymphoma 195  
 localized pagetoid reticulosis (Woringer-Kolopp) 42  
 lymphocytoma cutis 383
- marginal zone lymphoma 210  
 plasma cell granuloma 389  
 scabies, nodular 371  
 solitary idiopathic B/T-cell pseudolymphoma 256, 257  
 tattoos, pseudolymphomatous 385  
 T-cell/histiocyte-rich B-cell lymphoma, cutaneous 259
- Sweet's syndrome 296  
 "histiocytoid" *see* histiocytoid Sweet's syndrome  
 syphilis, pseudolymphomatous 386–388, 388, 389, 390  
 histopathology 387, 388, 389  
 "syringolymphoid hyperplasia with alopecia" 41  
 syringometaplasia 41, 44  
 systemic plasmacytosis *see* plasmacytosis
- tacrolimus, topical  
 actinic reticuloid 354  
 lymphocytoma cutis 383  
 tattoos, pseudolymphomas in 385, 386  
 tazarotene, mycosis fungoides 59  
 T-cell/histiocyte-rich B-cell lymphoma, cutaneous 258–259  
 histopathology and immunophenotype 259, 258  
 molecular genetics 259  
 treatment and prognosis 259  
 T-cell large granular lymphocytic leukemia 319  
 T-cell prolymphocytic leukemia (T-PLL) 317, 318  
 T-cell receptor (TCR)  
 gene rearrangement 4–5  
 silent (null-cell) 137  
 V $\beta$  repertoire 13  
 T-cell-rich angiomatoid polypoid pseudolymphoma 355, 356–357  
 T-cell-rich B-cell lymphoma *see* T-cell/histiocyte-rich B-cell lymphoma, cutaneous
- telangiectasia  
 intralymphatic CD30+ anaplastic large T-cell lymphoma 239  
 intravascular large B-cell lymphoma 233, 233  
 poikilodermatous mycosis fungoides 48  
 testicular B-cell lymphoma 220  
 T follicular (T<sub>FH</sub>) cells  
 in angioimmunoblastic T-cell lymphoma *see* angioimmunoblastic T-cell lymphoma  
 CD4+ small-medium T-cell lymphoma, cutaneous 163, 164, 167–168  
 mycosis fungoides 25, 33  
 neoplastic differentiation towards 168  
 peripheral T-cell lymphoma, NOS 157  
 Sézary syndrome 79  
 in T-follicular helper (T<sub>FH</sub>)-cell lymphoma, cutaneous *see* T-follicular helper (T<sub>FH</sub>)-cell lymphoma, cutaneous  
 lymphoma, cutaneous  
 T-follicular helper (T<sub>FH</sub>)-cell lymphoma, cutaneous 9, 167–168
- thalidomide  
 anaplastic large cell lymphoma 109  
 IgG4-related disease 386  
 pseudolymphomas at sites of vaccination 385  
 therapy-resistant dermatitis 20  
 T-lymphoblastic lymphoma, cutaneous 323–325  
 clinical features 323, 324, 325  
 histopathology and immunophenotype 323, 323
- molecular genetics 323–325  
 treatment and prognosis 325  
 TNM classification, cutaneous lymphomas 99, 100
- total body irradiation  
 mycosis fungoides 59  
 Sézary syndrome 80
- transdifferentiation 4, 28  
 chronic myelogenous leukemia 296  
 cutaneous follicle center lymphoma 185
- T-regulatory (Treg) cells  
 adult T-cell leukemia/lymphoma 172  
 lymphomatoid papulosis 86  
 mycosis fungoides 27, 30, 33  
 peripheral T-cell lymphoma, NOS 157  
 Sézary syndrome 79  
*Treponema pallidum* 387, 388, 390  
 trichophytia, pseudolymphomatous 368, 370  
 tumor vaccines, mycosis fungoides 59
- ulcero-necrotic PLEVA *see* pityriasis lichenoides et varioliformis acuta (PLEVA)
- ulcus rodens 14, 18
- ultraviolet light A (UV-A) therapy *see* PUVA  
 ultraviolet light B (UV-B) therapy  
 actinic reticuloid 353  
 B-cell chronic lymphocytic leukemia 291  
 mycosis fungoides 57  
 follicular mycosis fungoides 42  
 unclassifiable cutaneous lymphoma 413, 414
- vaccination, pseudolymphoma at sites of 384, 384–385, 385  
 varicella zoster virus infections 371–372, 372  
 venous stasis ulceration 121  
 viral warts, pseudolymphoma at sites of 368  
 viruses 6  
*see also* specific viruses
- vitiligo 360, 360–361
- Waldenström macroglobulinemia 2, 208  
 warts, pseudolymphoma at sites of 368  
 "watchful waiting" treatment strategy  
 atypical lymphoid proliferations 414  
 follicle center lymphoma 195  
 lymphomatoid papulosis 99  
 marginal zone lymphoma 208, 210, 211  
 mycosis fungoides 58  
 pre-tibial lymphoplasmacytic plaque in children 394
- Weber-Christian panniculitis 120  
 WHO classification 1, 2–3  
*see also* specific entities
- WHO-EORTC classification 1, 4  
 comparison with WHO classification 4  
*see also* specific entities
- Woringer-Kolopp type of mycosis fungoides 33, 33, 41–42, 46, 47, 55, 341  
*see also* pagetoid reticulosis
- World Health Organization *see* WHO
- xanthoerythroderma perstans 13, 15, 34
- zoster, pseudolymphoma in 371–372, 372, 373  
 zosteriform mycosis fungoides 33





